
Opinion|Videos|March 13, 2025
Emerging ADC Clinical Trial Evidence in Breast Cancer Treatment
Panelists discuss how emerging antibody-drug conjugates (ADCs) in metastatic breast cancer (mBC) treatment demonstrate innovation through optimized drug-to-antibody ratios, novel payloads, and targeted approaches to different breast cancer subtypes. Key trials explore combinations with established therapies and potential for improved tolerability profiles. Additional notable studies include comparative effectiveness research between approved ADCs and investigation of biomarker-driven patient selection strategies to maximize therapeutic benefit while minimizing adverse effects.
Advertisement
Episodes in this series

Video content above has been prompted by the following:
- How do emerging ADCs in clinical trials (eg, DB-1303/BNT323, patritumab deruxtecan, zanidatamab) demonstrate innovative approaches to treating mBC?
- Aside from emerging ADCs, please describe other clinical trials that may be of interest to pharmacists in this space (eg, head-to-head comparisons of approved ADCs).
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Yes, COVID-19 Is Still a Big Deal. Pharmacy Is the Tip of the Spear (and Needle)
2
Beat the Heat: 10 Common Medication Culprits Causing Heat Intolerance
3
FDA Fast Tracks First-in-Class TNFR2 Antibody as Chemotherapy-Free Strategy for Platinum-Resistant Ovarian Cancer
4
The Inflation Reduction Act and Oncology Drug Pricing: What Pharmacists Need to Know
5



































































































